Eisai Wins Patent Lawsuit For Proton Pump Inhibitor AcipHex
This article was originally published in PharmAsia News
Executive Summary
TOKYO - In a decision that would bolster its underlying profit-making structure and spur its intellectual property protection policy, Eisai July 22 said it won a patent lawsuit for its proton pump inhibitor AcipHex, one of its two leading global pharmaceutical products, in the U.S
You may also be interested in...
Astellas, Boehringer Sue Impax For Prostate Drug Patent Infringement
TOKYO - Moving in concert with the Japanese government's policy to toughen intellectual property rights protection, Astellas, jointly with Boehringer Ingelheim Pharmaceuticals, filed a patent infringement lawsuit in the United States against Impax Laboratories for Astellas' prostate treatment drug, the company announced July 22
Astellas, Boehringer Sue Impax For Prostate Drug Patent Infringement
TOKYO - Moving in concert with the Japanese government's policy to toughen intellectual property rights protection, Astellas, jointly with Boehringer Ingelheim Pharmaceuticals, filed a patent infringement lawsuit in the United States against Impax Laboratories for Astellas' prostate treatment drug, the company announced July 22
Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs
Already cleared for gastroesophageal reflux disease in adults, Eisai's Aciphex won U.S. FDA clearance June 30 for short-term use by adolescents age 12 and higher